Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, hard capsules, and other health foods. I… Read more
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) - Net Assets
Latest net assets as of September 2025: CN¥94.30 Million CNY
Based on the latest financial reports, Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has net assets worth CN¥94.30 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥429.73 Million) and total liabilities (CN¥335.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥94.30 Million |
| % of Total Assets | 21.94% |
| Annual Growth Rate | -0.05% |
| 5-Year Change | -8.91% |
| 10-Year Change | 35.47% |
| Growth Volatility | 210.01 |
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Net Assets Trend (1993–2024)
This chart illustrates how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1993–2024)
The table below shows the annual net assets of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1993 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥85.02 Million | +51.96% |
| 2023-12-31 | CN¥55.95 Million | +1148.93% |
| 2022-12-31 | CN¥4.48 Million | -93.06% |
| 2021-12-31 | CN¥64.56 Million | -30.83% |
| 2020-12-31 | CN¥93.33 Million | -30.00% |
| 2019-12-31 | CN¥133.33 Million | +63.34% |
| 2018-12-31 | CN¥81.62 Million | -15.21% |
| 2017-12-31 | CN¥96.27 Million | +45.45% |
| 2016-12-31 | CN¥66.18 Million | +5.46% |
| 2015-12-31 | CN¥62.76 Million | -26.38% |
| 2014-12-31 | CN¥85.25 Million | -10.51% |
| 2013-12-31 | CN¥95.26 Million | +2.70% |
| 2012-12-31 | CN¥92.76 Million | -49.27% |
| 2011-12-31 | CN¥182.84 Million | +18.62% |
| 2010-12-31 | CN¥154.14 Million | -17.90% |
| 2009-12-31 | CN¥187.74 Million | -21.87% |
| 2008-12-31 | CN¥240.30 Million | -15.07% |
| 2007-12-31 | CN¥282.93 Million | +19.66% |
| 2006-12-31 | CN¥236.44 Million | -1.23% |
| 2005-12-31 | CN¥239.39 Million | -5.14% |
| 2004-12-31 | CN¥252.36 Million | +4.01% |
| 2003-12-31 | CN¥242.64 Million | -4.17% |
| 2002-12-31 | CN¥253.20 Million | +0.62% |
| 2001-12-31 | CN¥251.63 Million | +0.14% |
| 2000-12-31 | CN¥251.29 Million | +2.94% |
| 1999-12-31 | CN¥244.10 Million | +3.56% |
| 1998-12-31 | CN¥235.71 Million | +4.64% |
| 1997-12-31 | CN¥225.25 Million | +11.78% |
| 1996-12-31 | CN¥201.52 Million | +15.80% |
| 1995-12-31 | CN¥174.02 Million | -- |
| 1994-12-31 | CN¥0.00 | -- |
| 1993-12-31 | CN¥86.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2960.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥121.78 Million | 232.47% |
| Other Components | CN¥186.97 Million | 356.92% |
| Total Equity | CN¥52.38 Million | 100.00% |
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Competitors by Market Cap
The table below lists competitors of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CELON PHARMA S.A. ZY-10
F:8RP
|
$126.43 Million |
|
lastminute.com N.V
PINK:LSMNF
|
$126.49 Million |
|
Mokingran Jewellery Group Co., Ltd.
F:0HY
|
$126.52 Million |
|
Clasquin
PA:ALCLA
|
$126.60 Million |
|
United Pharm
KO:033270
|
$126.28 Million |
|
Journey Medical Corp
NASDAQ:DERM
|
$126.26 Million |
|
Cool Company Oy
OL:CLCO
|
$126.25 Million |
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
$126.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 37,138,057 to 52,383,884, a change of 15,245,827 (41.1%).
- Net income of 15,245,827 contributed positively to equity growth.
- Dividend payments of 8,583,889 reduced retained earnings.
- Other factors increased equity by 8,583,889.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥15.25 Million | +29.1% |
| Dividends Paid | CN¥8.58 Million | -16.39% |
| Other Changes | CN¥8.58 Million | +16.39% |
| Total Change | CN¥- | 41.05% |
Book Value vs Market Value Analysis
This analysis compares Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 49.59x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 30.04x to 49.59x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | CN¥0.71 | CN¥21.33 | x |
| 1994-12-31 | CN¥0.91 | CN¥21.33 | x |
| 1995-12-31 | CN¥1.09 | CN¥21.33 | x |
| 1996-12-31 | CN¥1.26 | CN¥21.33 | x |
| 1997-12-31 | CN¥1.32 | CN¥21.33 | x |
| 1998-12-31 | CN¥1.39 | CN¥21.33 | x |
| 1999-12-31 | CN¥1.43 | CN¥21.33 | x |
| 2000-12-31 | CN¥1.43 | CN¥21.33 | x |
| 2001-12-31 | CN¥1.41 | CN¥21.33 | x |
| 2002-12-31 | CN¥1.41 | CN¥21.33 | x |
| 2003-12-31 | CN¥1.34 | CN¥21.33 | x |
| 2004-12-31 | CN¥1.39 | CN¥21.33 | x |
| 2005-12-31 | CN¥1.31 | CN¥21.33 | x |
| 2006-12-31 | CN¥1.55 | CN¥21.33 | x |
| 2007-12-31 | CN¥1.84 | CN¥21.33 | x |
| 2008-12-31 | CN¥1.65 | CN¥21.33 | x |
| 2009-12-31 | CN¥1.42 | CN¥21.33 | x |
| 2010-12-31 | CN¥1.12 | CN¥21.33 | x |
| 2011-12-31 | CN¥1.40 | CN¥21.33 | x |
| 2012-12-31 | CN¥0.63 | CN¥21.33 | x |
| 2013-12-31 | CN¥0.74 | CN¥21.33 | x |
| 2014-12-31 | CN¥0.58 | CN¥21.33 | x |
| 2015-12-31 | CN¥0.48 | CN¥21.33 | x |
| 2016-12-31 | CN¥0.48 | CN¥21.33 | x |
| 2017-12-31 | CN¥0.57 | CN¥21.33 | x |
| 2018-12-31 | CN¥0.42 | CN¥21.33 | x |
| 2019-12-31 | CN¥0.84 | CN¥21.33 | x |
| 2020-12-31 | CN¥0.60 | CN¥21.33 | x |
| 2021-12-31 | CN¥0.37 | CN¥21.33 | x |
| 2022-12-31 | CN¥-0.12 | CN¥21.33 | x |
| 2023-12-31 | CN¥0.30 | CN¥21.33 | x |
| 2024-12-31 | CN¥0.43 | CN¥21.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 29.10%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.02%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 8.43x
- Recent ROE (29.10%) is above the historical average (-8.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 11.52% | 23.18% | 0.38x | 1.31x | CN¥1.31 Million |
| 1994 | 10.69% | 27.24% | 0.30x | 1.33x | CN¥1.00 Million |
| 1995 | 7.79% | 20.41% | 0.25x | 1.52x | CN¥-3.81 Million |
| 1996 | 10.37% | 28.11% | 0.29x | 1.29x | CN¥745.14K |
| 1997 | 10.06% | 22.33% | 0.32x | 1.41x | CN¥121.17K |
| 1998 | 10.26% | 17.49% | 0.40x | 1.47x | CN¥563.65K |
| 1999 | 6.09% | 10.06% | 0.41x | 1.49x | CN¥-8.90 Million |
| 2000 | 1.10% | 2.64% | 0.23x | 1.79x | CN¥-20.18 Million |
| 2001 | 1.50% | 2.33% | 0.35x | 1.82x | CN¥-19.07 Million |
| 2002 | 0.88% | 1.24% | 0.42x | 1.67x | CN¥-20.40 Million |
| 2003 | -5.48% | -5.93% | 0.57x | 1.63x | CN¥-32.95 Million |
| 2004 | 3.12% | 3.29% | 0.59x | 1.62x | CN¥-15.21 Million |
| 2005 | 1.77% | 1.54% | 0.64x | 1.80x | CN¥-17.08 Million |
| 2006 | 0.19% | 0.15% | 0.74x | 1.71x | CN¥-20.24 Million |
| 2007 | 6.63% | 5.70% | 0.64x | 1.82x | CN¥-7.69 Million |
| 2008 | 1.81% | 1.61% | 0.69x | 1.64x | CN¥-18.40 Million |
| 2009 | -30.27% | -21.29% | 0.75x | 1.90x | CN¥-69.50 Million |
| 2010 | -6.28% | -3.77% | 0.73x | 2.27x | CN¥-22.90 Million |
| 2011 | 15.74% | 9.54% | 0.77x | 2.13x | CN¥9.64 Million |
| 2012 | -120.11% | -39.98% | 0.77x | 3.88x | CN¥-99.22 Million |
| 2013 | 2.69% | 0.75% | 0.87x | 4.15x | CN¥-5.73 Million |
| 2014 | 3.45% | 1.82% | 0.52x | 3.63x | CN¥-5.16 Million |
| 2015 | -37.67% | -22.73% | 0.34x | 4.90x | CN¥-27.26 Million |
| 2016 | 2.06% | 0.98% | 0.40x | 5.19x | CN¥-4.68 Million |
| 2017 | 10.85% | 4.07% | 0.39x | 6.81x | CN¥564.14K |
| 2018 | -19.18% | -2.76% | 0.75x | 9.33x | CN¥-15.02 Million |
| 2019 | 49.78% | 17.06% | 0.56x | 5.18x | CN¥40.50 Million |
| 2020 | -70.77% | -24.95% | 0.47x | 6.07x | CN¥-58.83 Million |
| 2021 | -72.55% | -22.29% | 0.37x | 8.91x | CN¥-37.30 Million |
| 2022 | 0.00% | -67.22% | 0.36x | 0.00x | CN¥-71.75 Million |
| 2023 | -103.06% | -31.43% | 0.35x | 9.32x | CN¥-41.99 Million |
| 2024 | 29.10% | 7.02% | 0.49x | 8.43x | CN¥10.01 Million |
Industry Comparison
This section compares Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,443,093,618
- Average return on equity (ROE) among peers: -7.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) | CN¥94.30 Million | 11.52% | 3.56x | $126.36 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $177.19 Million | 13.55% | 0.63x | $201.14 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $280.61 Million | 7.70% | 0.99x | $310.45 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $638.18 Million | -181.03% | 3.22x | $202.85 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $477.68 Million | 3.28% | 0.64x | $234.89 Million |
| Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) | $361.29 Million | 26.02% | 0.32x | $146.91 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $9.15 Billion | 2.09% | 0.37x | $1.03 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $278.08 Million | 2.72% | 0.13x | $459.10 Million |
| Chongqing Lummy Pharmaceutical (300006) | $107.91 Million | 22.70% | 0.99x | $476.38 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $1.44 Billion | 5.91% | 0.29x | $1.19 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $1.53 Billion | 18.22% | 0.05x | $893.48 Million |